8-K: Summit Therapeutics Announces Positive Phase III Trial Results for Ivonescimab in Lung Cancer

Summit Therapeutics reported that ivonescimab significantly improved progression-free survival compared to pembrolizumab in patients with PD-L1 positive advanced non-small cell lung cancer.

Summary

• Summit Therapeutics announced positive results from the HARMONi-2 Phase III trial, where ivonescimab showed a statistically significant improvement in progression-free survival (PFS) compared to pembrolizumab in patients with PD-L1 positive advanced non-small cell lung cancer (NSCLC).
• The median PFS was 11.14 months for ivonescimab compared to 5.82 months for pembrolizumab, with a hazard ratio of 0.51.
• This benefit was observed across various subgroups, including patients with both high and low PD-L1 expression, as well as squamous and non-squamous histologies.
• The overall response rate (ORR) was 50.0% for ivonescimab and 38.5% for pembrolizumab, while the disease control rate (DCR) was 89.9% and 70.5%, respectively.
• The safety profile of ivonescimab was manageable, with similar rates of serious treatment-related adverse events (TRAEs) and TRAE-led discontinuations compared to pembrolizumab.
• Additionally, Phase II data for perioperative ivonescimab in resectable NSCLC showed promising results, with a major pathological response (MPR) rate of 71.8% and a pathological complete response (pCR) rate of 43.6% when combined with chemotherapy.
• Three additional Phase II trials in other solid tumor settings will be presented at the European Society of Medical Oncology (ESMO) Congress 2024.

Sentiment

Score: 9

Explanation: The document presents highly positive clinical trial results for ivonescimab, showing significant improvements over a standard treatment. The planned initiation of a new Phase III trial further reinforces the positive outlook. The sentiment is very strong, indicating a high likelihood of positive market reaction.

Positives

• Ivonescimab significantly improved progression-free survival compared to pembrolizumab in the HARMONi-2 trial.
• The PFS benefit was consistent across various patient subgroups, including those with different PD-L1 expression levels and tumor histologies.
• Ivonescimab showed higher ORR and DCR compared to pembrolizumab.
• The safety profile of ivonescimab was manageable and consistent with previous studies.
• Perioperative use of ivonescimab combined with chemotherapy showed promising pathological response rates in resectable NSCLC.
• The company plans to initiate a new Phase III trial (HARMONi-7) based on the positive results.

Negatives

• There were slightly higher rates of Grade 3+ proteinuria and hypertension in the ivonescimab arm compared to the pembrolizumab arm.
• One patient in the ivonescimab arm and two patients in the pembrolizumab arm died as a result of treatment-related adverse events in the HARMONi-2 trial.
• Grade 3 or higher adverse events that were possibly VEGF-related were higher in the ivonescimab arm (10.2%) compared to the pembrolizumab arm (1.0%).

Risks

• The safety profile of ivonescimab, while manageable, includes higher rates of certain adverse events like proteinuria and hypertension.
• The overall survival data for the HARMONi-2 trial is not yet mature and will be evaluated in the future.
• The success of future trials, including HARMONi-7, is not guaranteed.
• Regulatory approvals for ivonescimab in Summit's licensed territories are not yet secured.
• The company's ability to execute its clinical development plan and commercialize ivonescimab depends on various factors, including funding and regulatory outcomes.

Future Outlook

Summit plans to initiate the HARMONi-7 Phase III trial in early 2025, comparing ivonescimab monotherapy to pembrolizumab monotherapy in patients with high PD-L1 expressing metastatic NSCLC. The company also plans to share additional details about its expanded clinical development plan in early 2025.

Management Comments

• Robert W. Duggan, Chairman and Chief Executive Officer of Summit, stated that this is the beginning of a landscape shift for treatment options for patients living with cancer.
• Dr. Maky Zanganeh, Chief Executive Officer and President of Summit, added that ivonescimab has the potential to be the next generation in PD-1 directed immunotherapy.

Industry Context

The announcement is significant as it presents a potential new first-line treatment option for NSCLC, a major area of unmet medical need. The positive results of ivonescimab compared to pembrolizumab, a standard of care, could position it as a strong competitor in the market. The data also highlights the growing importance of bispecific antibodies in cancer treatment.

Comparison to Industry Standards

• The HARMONi-2 trial results show a significant improvement in PFS compared to pembrolizumab, which is a widely used first-line treatment for NSCLC. This is a notable achievement as many trials have failed to show superiority over pembrolizumab.
• The median PFS of 11.14 months with ivonescimab is clinically meaningful and compares favorably to other first-line treatments for NSCLC.
• The perioperative NSCLC data, with a pCR rate of 43.6% for ivonescimab plus chemotherapy, is also encouraging when compared to historical data from other studies in similar settings, such as KEYNOTE-671, CheckMate 77T, AEGEAN, Neotorch, and RATIONALE 315.
• The safety profile of ivonescimab appears manageable, with similar rates of serious TRAEs and TRAE-led discontinuations compared to pembrolizumab, which is important for its potential adoption.

Stakeholder Impact

• Shareholders are likely to react positively to the strong clinical trial results and the potential for ivonescimab to become a significant product.
• Patients with NSCLC may benefit from a new treatment option that has shown improved efficacy compared to existing therapies.
• Employees of Summit Therapeutics may experience increased job security and opportunities due to the positive developments.
• Akeso, Summit's collaboration partner, will also benefit from the success of ivonescimab.

Next Steps

• Summit plans to initiate the HARMONi-7 Phase III clinical trial in early 2025.
• The company will present additional Phase II data at the ESMO Congress 2024.
• Summit will continue to evaluate the overall survival data from the HARMONi-2 trial.
• The company will continue clinical development of ivonescimab in NSCLC and other tumor types.

Key Dates

Keywords

ivonescimab, NSCLC, lung cancer, pembrolizumab, immunotherapy, bispecific antibody, PD-L1, VEGF, clinical trial, HARMONi-2, HARMONi-7, Akeso, progression-free survival, overall response rate, perioperative, chemotherapy